Free Newsletter
Researchers uncover new ways to treat chronic infections
Researchers at a university in New York have identified three key regulators required for the formation and development of biofilms--a discovery that could lead to new ways of treating chronic infections.
Biofilms--communities of bacteria in self-produced slime that are difficult to eradicate--are implicated in more than 80 percent of chronic inflammatory and infectious diseases, including ear infections, gastrointestinal ulcers, urinary tract infections and pulmonary infections in cystic fibrosis patients, according to the Centers for Disease Control.
But through their research, Karin Sauer, associate professor of biology at Binghamton University, State University of New York, and graduate student Olga Petrova have "identified three novel two-component regulatory systems that were required for the development and maturation of P. aeruginosa biofilms," according to their findings published recently in PLoS Pathogens.
"If we can figure out how to make use of this newly discovered genetic program, we can interfere with the formation of biofilms and either prevent or treat biofilm infections more successfully," Sauer says in a statement.
Sauer's research is supported by the National Institutes of Health, which has awarded her more than $3 million, and the Army Research Office. Her two major NIH-funded projects, which began this fall, look at different aspects of biofilms. One focuses on antibiotic resistance and the mechanism behind it; the other centers on dispersion, the process by which a biofilm breaks down into individual bacterial cells.
- read the press release
- check out the results published in PLoS Pathogens
Related Articles:
Emerging Drug Developer: Transave
Tools speed contaminant detection
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





SHARE
WITH: